Study reveals people who experience intense visual imagery during a Ganzflicker test have naturally lower frequency rhythms in the visual cortex, making them more susceptible to pseudo-hallucinations.
PsychLight, a newly developed genetically encoded fluorescent sensor, helped researchers identify a psychedelic compound that acts on beneficial neural pathways to treat psychiatric disorders without the hallucinogenic effect.
Mouse study reveals elevated dopamine levels preceded hallucination-like events, and artificially boosting dopamine levels induced more hallucination-like events. The behavioral effects could be blocked by administering haloperidol, an antipsychotic which blocks dopamine. The study sheds light on potential new treatments for psychotic disorders marked by hallucinations.
Loneliness, stress, and social isolation as a result of COVID-19 exacerbated and intensified visual hallucinations in blind people with Charles Bonnet Syndrome by 56%.
Inducing hallucinations using visual stimuli in a lab setting enables more objective and reliable testing.
8% of patients with a history of seizures reported experiencing hallucinations. Of the 8%, 53% reported one or more suicide attempts. Findings suggest hallucinations associated with seizures are not just incidental but are a marker for mental health risks and suicidal behavior.
A new study reports hyper-connectivity between substructures of the thalamus, and the cerebral cortex may be responsible for auditory hallucinations associated with schizophrenia.
The strength of a person's mental imagery is associated with excitability in the prefrontal cortex and visual cortex. Highly excitable neurons in the visual cortex may reduce a person's ability to imagine mental images. The findings shed light on how aphantasia, a condition where a person can not imaging mental images, may occur.